1-2 of 2
Mony Morisse
Close
Sort by
Journal Articles

Isatuximab Plus Pomalidomide/Low-Dose Dexamethasone Versus Pomalidomide/Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (ICARIA-MM): Characterization of Subsequent Antimyeloma Therapies

Paul G. Richardson, Aurore Perrot, Jesús San-Miguel, Meral Beksac, Ivan Spicka, Xavier Leleu, Fredrik Schjesvold, Philippe Moreau, Meletios A. Dimopoulos, Jeffrey SY Huang, Jiri Minarik, Michele Cavo, H. Miles Prince, Sandrine Macé, Laure Malinge, Franck Dubin, Mony Morisse, Kenneth C. Anderson
Journal: Blood
Blood (2022) 140 (Supplement 1): 608–610.
https://doi.org/10.1182/blood-2022-159710
Published: 2022
Journal Articles

Isatuximab in Combination with Lenalidomide and Dexamethasone in Patients with High-Risk Smoldering Multiple Myeloma: Updated Safety Run-in Results from the Randomized Phase 3 Ithaca Study

Maria-Victoria Mateos, Paula Rodriguez Otero, Youngil Koh, Joaquin Martinez-Lopez, Gurdeep Parmar, H. Miles Prince, Hang Quach, Paz Ribas, Emil Hermansen, Vania T.M. Hungria, Sevgi Kalayoglu Besisik, Jin Seok Kim, Xavier Leleu, Valdas Pečeliūnas, Fredrik Schjesvold, Omur G. Sevindik, Tatiana Lavrova, Franck Dubin, Christine Devisme, Lucie Lepine, Sandrine Macé, Mony Morisse, Irene Ghobrial
Journal: Blood
Blood (2022) 140 (Supplement 1): 7317–7319.
https://doi.org/10.1182/blood-2022-157302
Published: 2022